Company intelligence / Profile preview

Telavant

New York, New York, United Statesroche.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Telavant developed RVT-3101, an anti-TL1A monoclonal antibody for inflammatory bowel diseases. In a mid-stage trial in ulcerative colitis, about 30% of patients achieved clinical remission at the intended dose after 14 weeks; endoscopic improvement was seen in over one-third of participants. One-year data showed sustained and improved benefits. The drug is advancing to global Phase 3 trials under Roche.

Therapeutic areas: Gastroenterology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Drug pipeline

1 asset

RVT-3101

Phase 2

Indications: Inflammatory bowel disease, Eosinophilic esophagitis

Partnerships

Roivant Sciences [founding parent]Pfizer [minority stakeholder, commercial rights ex-US/Japan, R&D collaboration on next-gen asset]

Beyond the preview

Go deeper on Telavant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telavant.

Explore the full profile